Compare MRLN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRLN | ANTX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.8M | 172.9M |
| IPO Year | 2024 | 2022 |
| Metric | MRLN | ANTX |
|---|---|---|
| Price | $1.15 | $3.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $7.92 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 3.9M | 315.3K |
| Earning Date | 11-15-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.23 | N/A |
| Revenue Next Year | $153.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $1.00 |
| 52 Week High | $17.00 | $7.19 |
| Indicator | MRLN | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.76 | 24.35 |
| Support Level | N/A | $2.87 |
| Resistance Level | $3.45 | $5.21 |
| Average True Range (ATR) | 0.14 | 0.43 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 8.52 | 9.40 |
Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.